UK markets closed

TaiwanJ Pharmaceuticals Co., Ltd. (6549.TWO)

Taipei Exchange - Taipei Exchange Delayed price. Currency in TWD
Add to watchlist
13.70-0.10 (-0.72%)
At close: 02:56PM CST

TaiwanJ Pharmaceuticals Co., Ltd.

No.2 ShengYi Road
Rm. 4, 3rd Floor, Sec.2 Hsinchu Biomedical Science Park Hsinchu County
Zhubei 302058
Taiwan
886 3 658 7721
https://www.taiwanj.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees11

Key executives

NameTitlePayExercisedYear born
Mr. Hung-Chang YuanGM & Director3.4MN/AN/A
Dr. Edwin Wu Ph.D.Founder & Honorary ChairmanN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company also develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.

Corporate governance

TaiwanJ Pharmaceuticals Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.